Aida Pharmaceuticals (AIDA)

[PaperProphet]

There are two items of high interest to me. The first is earnings. They have been strong in that area and hopefully that will continue. The quarterly report should be out in two or three weeks.

The second item of high interest to me is the actual results of the phase II trials of Rh-Apo2L; the p-value, statistics and all. When the company says initial results are "extremely positive" and show "strong efficacy," those are still only opinions. What one person sees as "extremely positive," another might see as "poor." There's a lot of risk when depending on someone's opinion of the results. However hard numbers aren't subject to interpretation. Good, objective data are a recipe for solid stock performance. That's generally why pharmaceutical companies do post that type of data in their press releases.